Fewer circulating CD4+PD‐L1+ and CD8+PD‐L1+ T cells correlate with improved progression‐free survival in patients with renal cell carcinoma receiving immune checkpoint inhibitors [21]. Here, CD274 is linked to renal cell carcinoma.